对此，《Current Oncology》杂志于2023年9月发表的一项Meta分析研究《A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)》（《一项评估HER2靶向治疗在HER2阳性转移性结直肠癌中疗效的Meta分析》）通过对现有文献的严格筛选和分析，系统评...
Targeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2)-positive (amplified and/or overexpressed) metastatic colorectal cancer (mCRC), and HER2 testing is indicated in patients with mCRC. At present, standard of care first-line treatment for those with HER2-...
KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Jun;17(6):738-746.
1. Seagen announces FDA accelerated approval of Tukysa (tucatinib) in combination with trastuzumab for people with previously treated RAS wild-type, HER2-positive metastatic colorectal cancer. News release. January 19, 2023. Accessed January 19, 2023. 2. Seagen announces results from pivotal MOUNTAINE...
16. Chang J, Xu M, Wang C, et al. Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: a result from HER2-FUSCC-G study. Clin Colorectal Cancer. 2022;21(4):347-353. doi:10.1016/j.clcc.2022.07.003 ...
[18] Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19(4):256-262.e2. 作者:黄玉庭;编辑:lsh 题图:丁香园创意团队...
[1] Seagen - Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer [2] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC...
6. Sartore‐Bianchi A, Trusolino L, Martino C, et al. Dual‐targeted therapy with trastuzumab and lapatinib in treatment‐refractory, KRAS codon 12/13 wild‐type, HER2‐positive metastatic colorectal cancer (HERACLES):...
参考来源:’ Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer’,新闻稿。Seagen Inc.;2022年7月2日发布。2022年7月5日访问。
Drug Designation Granted To Tucatinib For The Treatment Of HER2+ Metastatic Colorectal Cancer. Retrieved June 14, 2024, from https://www.biospace.com/article/releases/cascadian-therapeutics-announces-fda-orphan-drug-designation-granted-to-tucatinib-for-the-treatment-of-her2-metastatic-colorectal-cancer-...